

**ADDRESS GIVEN BY THE CHAIRMAN OF SIGMA PHARMACEUTICALS LIMITED
BRIAN JAMIESON, AT THE ANNUAL GENERAL MEETING ON WEDNESDAY 8 MAY 2013 IN
MELBOURNE, AUSTRALIA**

On behalf of the Board of Directors and employees of Sigma Pharmaceuticals Limited, I welcome you to our 2013 Annual General Meeting.

As the meeting is also being webcast, I would also like to extend a welcome to our on-line audience.

I have already introduced you to the Board and the Executive Team earlier in the meeting.

Also in attendance is our general management team, some of whom are new to the company in the past twelve months. I encourage you to have a chat with them after the meeting and hear firsthand about the activity that will be driving Sigma's future growth.

Firstly I would like to thank the leadership team for their hard work and commitment this year to ensure that Sigma maintains its positive momentum and continues to build a platform for growth.

Our CEO & Managing Director Mark Hooper will provide you with a summary of Sigma's financial performance over the past year and the future outlook.

Before handing over to Mark, I would like to review the past year.

Sigma delivered a strong underlying result this year, despite our additional investment in the business, the ongoing impact of PBS reform and the challenges facing retail in Australia.

These results were impacted by a class action settlement resulting in a one-off post-tax payout of \$33.6 million.

Adjusting for this, the strong health of the underlying business is reflected in the 4% rise in the Net Profit After Tax to \$52.3 million compared with \$50.3 million last year.

The Board was pleased to announce total shareholder dividends for the 2012/13 year, of 4.0 cents per share fully franked resulting in an overall pay-out ratio delivered to shareholders this financial year of 90% of underlying Net Profit After Tax.

Subject to our franking position and usual business considerations, our current cash outlook indicates that we should be able to maintain high payout levels for the foreseeable future.

This is consistent with the Board's strong commitment to continue rewarding shareholders for the improved financial performance of the company.

The on-market share buy-back has also continued and has resulted in 43.8 million shares being purchased to 7 May 2013, which represents around 4% of the potential 10%.

Since we last met, the Company has commenced a transformation program which will deliver ongoing benefits to the business. To date, Sigma has invested an additional \$15 million in people, infrastructure and processes and an additional \$5 million is in the pipeline.

Mark will expand on the detail behind this investment; the benefits of which I believe will become even more apparent in future years.

As part of the celebration of our 100th anniversary, Sigma shared with team members, brand members and other stakeholders highlights of our long history.

I was delighted to launch *Sigma – Celebrating 100 Years*; the wonderful account of the Sigma team, past and present, who continue to drive our business and show their ongoing commitment to serve community pharmacy. The book also celebrates the great partnerships Sigma has developed with our valued customers, suppliers and industry and community representatives.

You will find a pictorial snapshot of our 100 years in this year's Annual Review to commemorate our wonderful history.

In summary, the Board believes we have put shareholder returns at the forefront of our decision making. We've delivered around \$280 million of fully franked dividends since the beginning of 2011 and are very pleased at how the share price is responding to the company's progress.

Once again, thank you for being here today and showing your support for Sigma.

I would again like to take this opportunity to thank our CEO & Managing Director, Mark Hooper, my fellow Board members, senior management and all of Sigma's talented team for their ongoing contribution, commitment, energy and enthusiasm they create in the business.

We are confident that our strategy will continue to drive growth and value creation.

I look forward to sharing our progress with you in 2014.

Thank you.

Brian Jamieson

Chairman, Sigma Pharmaceuticals Limited

8 May 2013